LOS ANGELES, January 10, 2024 (Newswire.com)
-
In a groundbreaking collaboration, Beauty-Stem Biomedical, founded by the esteemed Dr. Chai Chin Lin, a dual Ph.D. graduate from Michigan State University, is teaming up with the S.Y. Dao Cancer Prevention Foundation. This dynamic partnership will unveil a charitable book lecture on CD34 stem cells and immunology, co-authored by Dr. Chai Chin Lin and S.Y. Dao's President Dr. Kuan Yiao Chen, an attending doctor at Veterans General Hospital.
The highly anticipated event promises an exhilarating experience as these biomedical experts delved into cutting-edge topics related to CD34 stem cells and cancer prevention.
Dr. Chai Chin Lin, a visionary professor, has not only founded Beauty-Stem Biomedical but also co-founded Power-Stem Biomedical, showcasing a commitment to pushing scientific boundaries. Armed with a dual Ph.D. from Michigan State University, Dr. Lin brings a wealth of knowledge to the collaboration, driving innovation in the quest for an innovative oral stem cell supplement, CD34 NU-Signals, in healthcare.
The charitable book lecture centers on CD34 stem cells and immunology, demystifying these cutting-edge scientific concepts for a broader audience. Dr. Lin and Dr. Chen aim to make complex topics accessible, turning the lecture into a platform for knowledge-sharing while contributing to the foundation's mission of promoting healthy lifestyle choices for cancer prevention.
As anticipation builds for this momentous occasion, individuals from all walks of life are encouraged to attend, enriching their understanding of CD34 stem cells, immunology, and the vital role lifestyle choices play in cancer prevention. The collaboration between Beauty-Stem Biomedical and S.Y. Dao Cancer Prevention Foundation marks a significant step towards a healthier, more informed society, poised to combat cancer challenges through knowledge and collaboration.
Contact Information:
Beauty-Stem Marketing
Media Department [email protected]
888-341-7505
Gb Sciences is focusing considerable resources on bringing its lead Parkinson's disease formulations to the clinic with promising results; plus, new data validating the efficacy of their novel anxiety formulations and demonstrating the improved stability of their oral nanoparticle-encapsulated chronic pain formulations add value to their drug development pipeline.
"Gb Sciences is focusing considerable resources on bringing our lead Parkinson's disease formulations to the clinic with promising results already obtained during the formulation of Oral Dissolving Tablets containing our active ingredients for use in human clinical trials," said Dr. Andrea Small-Howard, President, Chief Science Officer, and Director of Gb Sciences. "We have new data validating the efficacy of our novel anxiety formulations in an animal model, as well as new data demonstrating the improved stability of our oral nanoparticle-encapsulated chronic pain formulations based on newly-adopted manufacturing control processes."
The full article entitled "Unlocking the Therapeutic Potential of Plant-Inspired Minimum Essential Mixtures" also provides some context for their recent drug development successes by discussing Gb Sciences' evolution from a cannabis company to a plant-inspired biopharmaceutical company and what makes their drug development approach truly unique. With conventional drug discovery efforts failing to deliver on some critical medical needs, such as non-opioid treatments for chronic pain, there may be value in exploring plants associated with traditional medicines to discover new drug molecules and simplified mixtures. Gb Sciences is connecting plant-based medicine with modern in silico drug discovery tools, leveraging a unique AI-enabled platform to mine plant species and compounds to uncover minimum essential mixtures of molecules with therapeutic benefits and reduced side effect profiles.
Gb Sciences, Inc. is a plant-inspired, biopharmaceutical research and development company creating patented, disease-targeted formulations of cannabis- and other plant-inspired therapeutic mixtures for the prescription drug market through its Canadian subsidiary, GbS Global Biopharma, Inc. The 'plant-inspired' active ingredients in its therapeutic mixtures are synthetic homologues identical to the original plant compounds but produced under current Good Manufacturing Practices. Gb Sciences' intellectual property portfolio contains six issued U.S. and three issued foreign patents, as well as 17 U.S. and 51 foreign patent-pending applications. In its drug development pipeline, Gb Sciences has five preclinical phase product development programs. Gb Sciences' lead program for Parkinson's disease is being prepared for a first-in-human clinical trial. Gb Sciences' formulations for chronic pain, anxiety, and depression are currently in preclinical animal studies with researchers at the National Research Council Canada. The company also received positive preclinical proof-of-concept data supporting its complex mixtures for the treatment of Cytokine Release Syndrome related to COVID-19, and its lead candidates will be optimized based on late-stage preclinical studies at Michigan State University. Gb Sciences' productive research and development network includes distinguished universities, hospitals, and Contract Research Organizations. To learn more, visit www.gbsciences.com.
Forward-Looking Statements
This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
